iproplatin

Iproplatin is a synthetic, second-generation platinum-containing compound related to cisplatin. It acts as an antineoplastic agent by binding to and forming DNA crosslinks and platinum-DNA adducts, which result in the inhibition of DNA replication and ultimately lead to tumor cell death. Compared to cisplatin, it is less prone to glutathione inactivation but can still encounter resistance due to cellular repair mechanisms for platination damage. Iproplatin was investigated primarily for the treatment of various cancers, including ovarian carcinoma and advanced breast cancer. Its development was discontinued after phase III clinical trials due to limited efficacy and notable toxicities such as thrombocytopenia, myelosuppression, nausea, vomiting, diarrhea, neuropathy (in patients previously treated with cisplatin), and mild reversible renal toxicity[1][2][3][4][5][6][8][10].

Other names

iproplatin [INN]iproplatin [USAN]iproplatin [MART.]iproplatin [WHO-DD]